Bryant Furlow

Some patients with early HER2-positive breast cancer can safely forgo neoadjuvant chemotherapy, results of the PHERGain trial suggest.

Study patients were randomized to 1-hour IV fosfomycin 6g infusion every 8 hours (18 g total daily dose) or IV piperacillin/tazobactam 4.5g infused over 1 hour every 8 hours for a fixed 7 days.

Clinical and demographic profiles of patients were compared on those who completed the 9H vs. 3HP regimens with a focus on adverse events, which can commonly cause treatment discontinuation.

The ceftriaxone + doxycycline regimen has been favored in light of ‘recent concerns of increased cardiovascular risk associated with azithromycin

The researchers sought to determine the type and frequency of hormonal contraceptives and ART prescribed to women with HIV infection and prevalence of resulting drug to drug interaction potential.

Intravenous (IV) antibiotics such as CPT is indicated for ABSSSIs “but real world clinical comparative data is limited.”

Participants included 464 hospitalized adults with cUTI or AP diagnosis, randomly assigned to be administered either ZTI-01 or piperacillin/tazobactam for a fixed 7 days.

Omadacycline is a novel, broad-spectrum aminomethylcycline related to tetracyclines; the OASIS phase 3 trial investigated whether it was non-inferior to linezolid.

Whereas epidemiological risk factors for CDI among adults are well known, data is limited for children.

Researchers assessed the risk of febrile seizures following inactivated influenza vaccine and pneumococcal conjugate vaccine-13 during 2013-14 and 2014-15 flu seasons.